Strong AstraZeneca picks obesity market for further growth

9 November 2023

Britain’s biggest drugmaker AstraZeneca (LSE: AZN) has exceeded revenues expectations handily in the third quarter 2023, with robust demand in oncology leading the way.

Revenues were up 4% for the quarter at $11.5 billion, with earnings per share (EPS) reaching 89 cents.

AstraZeneca, which played a significant global role in tackling the novel coronavirus with its vaccine Vaxzevria and an antibody treatment, has now dropped out of the market altogether.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK